Skip to main content
. Author manuscript; available in PMC: 2022 Jun 27.
Published in final edited form as: Clin Cancer Res. 2021 Jun 17;27(17):4757–4767. doi: 10.1158/1078-0432.CCR-21-0903

Figure 3.

Figure 3.

A, More cytokines/chemokines were significantly upregulated by rank value at C2D2 compared with baseline in the triplet versus the doublet cohort. Some cytokines/chemokines were more significantly upregulated at C2D2 in triplet versus doublet cohorts, including IL10, CCL22, TNFα, CD40 and MCSF (P < 0.001), and CXCL10 (P = 0.002), CCL3 (P = 0.002), and CCL27 (P = 0.005). At baseline, samples were available from 9/9 and 17/17 patients on doublet and triplet therapy, respectively. At C2D2, samples were available from 6/9 and 16/17 patients on doublet and triplet therapy, respectively. B, Comparison of the fold change of cytokine/chemokine levels at C2D2 from baseline at different dose levels of APX005M demonstrated that CCL22, TNFα and CD40 were increased in patients at the highest APX005M dose (0.3 mg/kg) compared with the lowest dose (0.03 mg/kg; P < 0.001). CCL22 was the only chemokine significantly higher at the highest APX005M dose compared with the intermediate dose (0.1 mg/kg; P < 0.001).